Medical aesthetics company JETEMA said on the 9th that it signed a long-term exclusive supply contract worth about 19.9 billion won for its filler products with its local Thai partner i-ONE H&B. With this deal, JETEMA aims to further solidify its foothold in Thailand's filler market.
According to the company, the entire contracted volume will be exported to Thailand, and steady sales growth is expected through 2030. In particular, instead of a structure where quantities fluctuate with market conditions, this is a firm contract that specifies a minimum order quantity (MOQ), enhancing revenue stability.
i-ONE H&B must place a minimum order for JETEMA's "e.p.t.q. hyaluronic acid (HA) fillers" of 150,000 syringes next year and 140,000 syringes annually from 2027 to 2030. The contract also includes 100% advance payment terms and a clause stripping exclusivity if annual orders fall short, strongly securing performance of the agreement as collateral.
This five-year exclusive contract supports JETEMA's growth in the Thai market. Cumulative sales of e.p.t.q. bound for Thailand have already surpassed 16.28 billion won, and on that basis the company has established itself as No. 1 in Thailand's filler market.
A JETEMA official said, "As we have granted i-ONE H&B exclusive sales and distribution rights in Thailand, it will serve as a strategic springboard for strengthening control and expanding market share over the long term."